VC Fund Dossiers

1315 Capital is a solid mid-tier fund that actually knows their sectors, especially healthcare where Nikhil Krishnan brings real expertise and network. They're not going to lead your Series C, but they can be genuinely helpful at Series A/B with operational support and introductions. Chris Sugden has been-there-done-that credibility as a former operator. The fund is still relatively new (launched 2020) so track record is limited, but early portfolio companies speak positively about their involvement. They won't give you the brand name cachet of top-tier funds, but they also won't ghost you post-investment.

3M Ventures is the rare corporate VC that actually knows what they're talking about when it comes to deep tech and manufacturing. They bring genuine technical expertise and can open doors to pilot programs with 3M's massive industrial customer base. The flip side? They move at corporate speed, decisions take forever, and there's always the strategic acquisition shadow hanging over everything. If your tech genuinely complements 3M's business, they're incredibly valuable partners. If not, you're probably better off with traditional VCs who won't spend six months debating internal synergies.

3one4 is one of the more competent mid-tier Indian VCs that actually adds value beyond just writing checks. The Pai duo (no relation) knows their stuff and has built a solid track record with companies like Razorpay becoming genuine successes. They're operationally savvy and won't ghost you post-investment, which is more than you can say for many Indian funds. That said, they're not top-tier brand name VCs, so don't expect them to open every door or lead your Series B. They're workmanlike investors who do their homework and genuinely try to help, but they won't make you cool at founder dinners.

5AM is one of the smarter life sciences funds that actually gets the tech side of biotech. They're not just former Big Pharma folks writing checks — they understand computational platforms and can help you navigate both the science and the business. The partners are genuinely helpful post-investment and have solid pharma connections for partnerships. However, they're picky as hell and move slower than software VCs, so don't expect quick decisions. They also tend to want meaningful board seats and operational input, which is great if you want the help but can feel heavy-handed if you don't.

7wire is one of the few healthcare-only funds that actually gets it - they're not generalist VCs pretending to understand healthcare. Shapiro and Garrity have real operational chops and extensive healthcare networks that matter when you're trying to sell to hospitals and health systems. They're particularly strong on go-to-market strategy and regulatory navigation. The downside? They can be quite selective and move slower than typical VCs due to their deep diligence process. If you're building outside of traditional healthcare delivery models, they might not be the right fit.

a16z Bio is the grown-up in the room for bio/healthtech investing. Unlike traditional biotech VCs who get spooked by tech, or tech VCs who don't understand FDA pathways, these folks actually get both sides. The partners have real operating experience and clinical backgrounds, which means they won't ask you to pivot to B2C when your B2B2C model hits regulatory hurdles. They're patient capital with 10+ year timelines, but expect you to show computational moats, not just wet lab progress. The a16z brand opens doors with pharma partnerships, but you'll need to prove platform scalability, not just single-asset potential.

This is a16z trying to buy their way into healthcare credibility, and it's actually working pretty well. The partners are solid — Vineeta knows her stuff technically, Julie has real operator experience, and they're building a legitimate healthcare network. They move fast when they want something and can write big checks, but you're getting the full a16z treatment: high expectations, lots of portfolio company cross-pollination, and pressure to think big. The flip side is they sometimes push companies to scale too aggressively before product-market fit is locked in. If you want maximum acceleration and can handle the intensity, they're legit.

Here's the real deal on A91: They're the 'Sequoia mafia' done right. Founded by three former Sequoia managing partners, they actually know how to build companies, not just write checks. Their $665M third fund closed in April 2025 was one of the largest VC fundraises in India, signaling serious LP confidence. The portfolio speaks volumes - Digit Insurance is expected to go public, and they've had partial exits from Atomberg and spice maker Pushp. What founders love: these guys actually get their hands dirty post-investment and have the operational chops to help scale. What to watch: they're raising average investment sizes to $35-40M with their new fund, so they're moving upmarket and may be less accessible for smaller rounds.

Aavishkaar is impact investing's OG in India - they've been doing 'business with purpose' since 2001 when most VCs were still chasing pure tech plays. While Aavishkaar Capital does focus on sustainable development goals, it stands at 3x Gross Multiple of Investment Capital (MOIC), in terms of returns. "We clock approximately 25 percent in terms of IRR as well. I don't think returns can be compromised just because we are called impact investors," Sushma says. That's solid performance for impact investing. But here's the thing - they're pivoting hard into climate and deeptech now, which means longer hold periods and more patient capital requirements. Track record is below average ... Less insightful than your average VC. Domain know-how limited to 1-2 sectors at best. Stingy culture - some Glassdoor reviews suggest internal culture issues and limited sector expertise beyond their core focus areas. They're great if you're building for underserved markets in financial inclusion or agtech, but expect a very thesis-driven, impact-first approach that may not suit pure growth plays.

AbbVie Ventures is the corporate VC arm that actually gets it - they move fast for a pharma giant and their checks are meaningful. The team has real scientific chops and can open doors at AbbVie proper, which matters when you need partnership or acquisition conversations. That said, they're not leading rounds and their investment committee can get spooked by anything too far outside AbbVie's wheelhouse. If your biotech aligns with their therapeutic areas, they're gold. If not, don't waste time - they stick to their knitting religiously.

Aberdare is healthcare VC royalty that's gone quiet. Paul Klingenstein has an enviable 25-year track record of picking billion-dollar winners like Omada, Nevro, and Castlight, but the fund has basically been sleepwalking since 2021 - their last investment was September 2021. They're the definition of old-school healthcare investors who understand the sector deeply but seem to have missed the AI/digital health wave that younger funds are riding. When they do invest, they write meaningful checks ($8M sweet spot) and actually know what they're doing, but good luck getting their attention right now. The Mohit Kaushal departure in 2014 left them without their digital health champion, and it shows.

Here's the deal: Abingworth got acquired by Carlyle in 2022 for $2 billion AUM, which means you're now dealing with a PE-backed entity, not an independent VC. This changes the dynamic entirely. The good news? They have serious biotech chops - 179 companies invested, 70 IPOs, 46 M&As, and their portfolio companies have secured 26 FDA approvals in the last 9 years alone. That's not marketing fluff, that's real execution. Founders consistently praise them as 'very engaged partners' with 'deep knowledge of the industry' and 'extensive networks' - the CEO testimonials are unusually glowing for biotech VCs. They've innovated with VIPEs (Venture Investments in Public Equities) for undervalued <$200M market cap biotechs, plus clinical co-development - so they're not just writing checks, they're creating new funding mechanisms. The Carlyle backing gives them serious firepower, but it also means they're playing with institutional money that has different return expectations than traditional VC funds.

ABS is the definition of a solid, unsexy regional fund that gets the job done. They're not going to win any innovation awards or get you TechCrunch headlines, but they actually know how to help B2B software companies scale profitably. Tim Weglicki will dig deep into your unit economics and hold you accountable to growth metrics - some founders love this discipline, others find it suffocating. They're particularly strong if you're in Baltimore/DC area and need someone who understands enterprise sales cycles. Don't expect them to lead hot consumer rounds or move at Silicon Valley speed, but they'll stick with you through tough times and actually know how to build sustainable businesses.

Acorn Pacific is the classic 'bridge fund' that actually delivers on the cross-border promise — they're not just marketing speak about Asia connections. Their track record shows real exits: 1 IPO and 5 acquisitions including key companies like NGINX, Crown Bioscience and Zhejiang Nuhui Health Technology. Derek Chau brings genuine operational chops from being a startup CEO himself, which founders appreciate. The Wu Fu Chen legacy gives them serious Silicon Valley street cred going back decades. But here's the thing — they have a portfolio of 30 companies spread thin across multiple markets, so don't expect white-glove attention. They're solid for founders who need real Asia-Pacific expansion help, not just another check.

Act met Barry Napier "over a decade ago" and made "the largest seed investment we possibly could" - this is a fund that bets big early and doubles down on winners. They explicitly say "We have never been the loudest venture firm" and "don't want to add to the noise of VCs making it about them." Strong exit track record including SilverCloud Health (acquired by Amwell), Decawave (acquired by Qorvo), and 34 total portfolio exits. Their strategy is clear: "find the best company builders at the earliest stages and continue to back them again and again." This isn't a spray-and-pray fund - they're conviction-driven, founder-focused, and have the dry powder (€140M Fund VI) to support you through multiple rounds.

Activate punches well above their weight class for a relatively young fund, with an impressive hit rate on fintech and B2B infrastructure plays. Hanan and team have solid operational chops and actually help with recruiting and business development, not just cheerleading. They're thesis-driven but not rigidly so, and move fast on deals they like. The downside? They're still building their brand and network compared to tier-one funds, so they might not be your best bet if you need marquee logos for your next round. But if you want investors who will roll up their sleeves and grind with you, they're legit.

Ada Ventures is one of the few VCs where the diversity talk isn't just marketing fluff — they've actually built systems to prove it works and attract better returns. Check Warner and Matt Penneycard are genuinely committed to their 'Inclusive Alpha' thesis, but be aware this isn't just about being nice — they're first and foremost a venture capital fund with their number one priority being exceptional returns for investors. They offer genuine founder support including free childcare through Bubble (30% of eligible founders use it) and hands-on talent help, with their Venture Partner Ben spending 10 weeks directly supporting Jack & Jill's hiring. They've built innovative tools like Deck Genius that give founders better feedback than most VCs provide, showing they genuinely want to elevate the ecosystem rather than just gatekeep it. The risk? Their mission-driven approach might mean they're pickier about founder values alignment than pure financial VCs.

Adjuvant Capital is what happens when the Gates Foundation alumni club decides to prove that doing good and making money aren't mutually exclusive in global health. Glenn Rockman and Jenny Yip are seasoned operators with serious pedigree - Rockman helped launch the $108M Global Health Investment Fund, and Yip ran strategic investments at Gates Foundation. They've attracted heavyweight LPs including Gates ($75M anchor), Novartis, Merck, and have already delivered exits with acquisitions of AN2 Therapeutics and others. They're not just writing checks - every investment comes with 'Global Access Commitments' to ensure products reach underserved populations, which is either admirable mission alignment or clever marketing to impact investors. The real test isn't their do-gooder credentials - it's whether they can generate actual returns while staying true to their access mission when the rubber meets the road.

ADM Ventures is the definition of strategic money with all the pros and cons that entails. The upside: they have massive distribution, can be your first enterprise customer, and understand complex food supply chains better than anyone. The downside: everything gets filtered through 'does this help ADM' which can limit your strategic flexibility. They're not going to lead competitive rounds against other food giants, and if your business model threatens their core operations, expect friction. Good operators but think like corporate development, not pure VCs.

Advent Life Sciences is the real deal - a proper company builder that actually gets drugs approved, not just another PowerPoint VC. Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A. Their crown jewel was KaNDy Therapeutics, which they spun out and sold to Bayer for $875 million - that's the kind of outcome that gets LPs' attention. The partners have genuine biotech operational experience, not just finance backgrounds, and they're hands-on without being micromanaging. They're particularly strong at company formation and early-stage value creation. The team is lean but experienced, with good transatlantic reach through their Boston presence. However, their portfolio is quite concentrated in traditional biopharma plays - if you're doing digital health or medical devices, this might not be your first call.

Aisling is the rare healthcare fund where the partners actually know what they're talking about - Dr. Schiff is still practicing medicine and sits on real boards, not just observer seats. Steven Elms brings serious Wall Street pedigree with 60+ transactions under his belt. They take an unusually active approach to investing and actually work closely with portfolio companies to build value and create multiple exit opportunities. The downside? Their flexible investment strategy across everything from seed to LBOs means you're competing with a much wider universe of opportunities for their attention. They're legitimate players with real exits, but don't expect hand-holding if you're just looking for a check.

AlbionVC is the grown-up in the room of UK venture - they've been doing this since 1996 and it shows in their disciplined, thesis-driven approach. Their partners project an aura of patience and take a genuinely long-term view, with reputation and consistency carrying more weight than flashy deals. Founders consistently praise Ed Lascelles specifically - Tony Pepper from Egress called him "equally important" to their success alongside the team and tech, while Quantexa's CEO said they've been privileged to work with Ed and AlbionVC from the beginning. They actually stick around - Quantexa went from first investment in 2017 to a $175m Series F at $2.6bn valuation in 2025, with AlbionVC participating in every round. The downside? They're not going to move fast on trendy deals, and if you want VC theater or ego stroking, look elsewhere.

This is the definition of corporate VC done right - except it's not really VC, it's real estate empire building with a science twist. Alexandria's secret sauce isn't just their money (they have plenty as a public REIT), it's that they own the buildings where biotech companies live and breathe. When they invest in you, they're betting you'll become their tenant, creating a beautiful conflict of interest that somehow works for everyone. They're one of the most prolific investors in the corporate VC space, but founders should know this isn't your typical Sand Hill Road partnership - they're thinking decades, not quick flips, which can be great for patient capital but frustrating if you need nimble decision-making.

AlleyCorp is the rare fund that actually knows how to build companies, not just write checks. Kevin Ryan's track record as an operator gives them credibility that most VCs lack, and they'll roll up their sleeves to help with everything from hiring to business development. The studio model means they're comfortable with pre-product companies and messy early stages. However, their New York focus can be limiting for West Coast founders, and their portfolio concentration in certain sectors means they might pass on great opportunities outside their comfort zone. They move fast on decisions but expect the same urgency from founders.

Cetin only looks 3-4 years ahead for exits and won't touch early-stage - 'I am like a goldfish,' he says. They're genuinely hands-on: every team member talks to their portfolio company CEOs at least twice a month. With almost €2bn AUM and 12 unicorns in their portfolio, they've got serious firepower. But they're conservative to a fault - passed on AI hype and blockchain, waiting for 'second wave' opportunities. The real value? Direct access to Allianz's massive customer base and distribution network for strategic partnerships.

Ally Bridge is essentially a cross-border specialist that made their name in the biotech boom, with some impressive exits like their early Moderna stake. They're genuinely well-connected in both US and Chinese markets, which is valuable if you need Asia-Pacific partnerships or expansion. However, they're pretty narrow in focus - if you're not in healthcare or don't have a clear Asia angle, you're probably not their cup of tea. They tend to be hands-on with portfolio companies, which some founders love and others find intrusive. The China connection is both their superpower and potential liability depending on current geopolitical winds.

Alpha JWC has grown from Indonesia's first independent early-stage venture capital fund into one of the region's most active and trusted investors, reflecting how Southeast Asia's innovation economy has evolved from early experimentation to a more disciplined pursuit of sustainable growth. Their portfolio has seen 6 unicorns, 2 IPOs and 15 acquisitions including key companies like Traveloka, Kopi Kenangan and WeWork. What founders say matters: "Alpha JWC has been a true partner on our transformation journey since day 1. The support that GudangAda has received from Alpha JWC, up until this very day, far exceeds capital injection". They're hands-on to a fault - the teams literally try every dish, every app, every coffee to give candid feedback. The downside? This founder-first obsession means they might overlook business fundamentals if they fall in love with a charismatic CEO.

Amadeus is one of the rare VCs that actually walks the walk on deep tech—they've been at it since 1997 when most funds were still figuring out what the internet was. As one founder, whose startup ContactEngine was acquired by NICE Systems, put it, landing investment from Amadeus meant securing one of "the best VCs in our space." Hermann Hauser's track record speaks for itself (he basically created ARM), and Anne Glover has built this into a proper institution. They are active investors who commonly take board seats and provide strategic advice, recruitment support, and introductions to international networks and corporate partners. The firm prides itself on being supportive yet measured, understanding when to step back and let the founders steer their company. The exit track record is genuinely impressive—multiple billion-dollar outcomes across different cycles. But here's the rub: they're extremely technical and will grill you hard on IP and defensibility. founders should be prepared for rigorous technical due diligence from Amadeus's experienced partners, many of whom bring a deep scientific background themselves.

Ampersand is the steady Eddie of healthcare investing - they know their lane and stick to it religiously. These guys have been doing healthcare growth deals since before it was cool and have genuine operational chops. They're not flashy or fast, but they're thorough and actually helpful post-investment. The catch? They move at healthcare industry speed (read: glacial) and their due diligence process can feel like getting a root canal. If you're a hot SaaS company looking for quick growth capital, look elsewhere. But if you're in healthcare services or HIT and want investors who actually understand your regulatory headaches and can help with acquisitions, they're solid.

Amplitude is a solid regional player that's punching above its weight class, especially if you're Canadian or selling into the Quebec market. They're operationally savvy and won't waste your time with fluffy advice - expect real, actionable feedback. The downside? Limited brand recognition outside Canada can hurt with customer acquisition and follow-on rounds from top-tier US funds. They're genuinely helpful post-investment but don't expect them to open doors at Google or Microsoft the way a Sequoia would.

Ananda is the real deal in European impact investing - they've actually proven it works with their first fund delivering 2x returns while creating measurable impact. Johannes and Florian are true believers who started this when impact investing was seen as 'philanthropy' and have built something genuinely differentiated. Their 'Impact Carry Model' legally ties partner compensation to portfolio companies hitting impact KPIs, not just financial returns - that's putting money where mouth is. The team thinks in systems, not sectors, and has a track record of backing winners like OroraTech and NatureMetrics before their markets were obvious. They're anti-consensus by design and have the technical chops to evaluate deep science plays. The €270M they now manage gives them real firepower, and their recent €73M Fund V close shows LPs believe in the model.

A16z Bio brings serious firepower and deep pockets, but you're getting the full Andreessen treatment - meaning lots of platform resources but also high expectations and board oversight. They're genuinely helpful on business model design and scaling challenges, especially if you're building something that intersects tech and bio. The partners actually know healthcare, which is rarer than you'd think. Downside: they're not afraid to bring in new management if things go sideways, and their brand attracts competitor attention early.

These two women have built something genuinely different in the Indian VC landscape - they're the anti-hype fund that actually gets shit done. While everyone else was chasing consumer internet unicorns, Ritu and Rema were quietly backing agritech in 2013 when no one cared, and deep science when it wasn't trendy. The physicist-cost accountant combo works: Ritu spots the technical breakthroughs, Rema makes sure the business fundamentals aren't trash. They stay invested longer than most VCs (till Series B/C) and actually roll up their sleeves post-investment. The downside? They're picky as hell and move methodically - if you need quick decisions or don't have real IP/science behind your startup, look elsewhere. But if you're solving hard problems with actual technology for overlooked markets, they're the best partners you'll find in India.

APEX Ventures is the rare European deep tech fund that actually understands what they're investing in - probably because their partners have real operational experience rather than just finance backgrounds. Andreas Riegler built and sold companies before becoming a VC, Wolfgang Neubert has deep technical expertise in photonics and quantum, and Gordon Euller is a practicing radiologist who worked at McKinsey. This translates into genuine value-add for founders wrestling with complex IP strategies and brutal commercialization timelines. The €80M Amadeus APEX Technology Fund partnership gives them serious firepower, and their portfolio companies consistently praise their hands-on support and network introductions. However, they're primarily focused on DACH region deals, so if you're not in Germany/Austria/Switzerland, you might be swimming upstream. Also, while they talk a good game about being 'founder-friendly,' deep tech investors by nature tend to want more control given the long development cycles and capital intensity.

Apposite is that rare breed - a genuinely healthcare-obsessed fund that actually knows what it's talking about. Nearly half their LPs are committed to healthcare impact investing, and their portfolio companies have achieved 20%+ annual revenue and employment growth on average - which is solid execution, not just marketing fluff. The Ulthera exit to Merz for up to $600M shows they can deliver returns, and founders consistently praise their hands-on approach. They're small with a flat hierarchy and human touch - think boutique healthcare specialists, not spreadsheet jockeys. The downside? £5M-£20M check sizes and £200M under management means they're playing in a specific sandbox - great if you fit, limiting if you don't. They're genuinely impact-focused, which is refreshing, but also means they'll pass on profitable healthcare plays that don't move the needle on patient outcomes.

Arboretum is a solid, if unspectacular, healthcare-focused fund that actually knows the space rather than just chasing healthcare as a hot sector. Tim Petersen and team have real operational chops and will roll up their sleeves to help with business development and strategic partnerships. The Michigan connection is real — they leverage University of Michigan resources and can help with talent and clinical partnerships. However, their check sizes are modest and they expect founders to be very metrics-driven from day one. Not the fund for moonshot science projects, but great for founders who want engaged partners who understand healthcare's unique challenges.

Arch is the real deal in life sciences - they've been doing this longer than almost anyone and have the exits to prove it. Their partners actually understand the science, not just the business model, which matters when you're betting on 10-year drug development timelines. They're patient capital with deep pockets and genuine operational expertise. The flip side? They're extremely selective and can be slow to move. If you're not Stanford/Harvard pedigreed or don't have a Nobel laureate on your team, getting their attention is tough. They also tend to take meaningful ownership stakes, so expect some control.

ARCH is the gold standard for biotech investing but they're not messing around with tourist entrepreneurs. They want founders who understand that building breakthrough science takes 7-10 years and $100M+ in capital. Nelsen has an almost mystical ability to spot winning biotech platforms early, but he'll grill you on the science until you cry. They're incredibly supportive if you make the cut - legendary for helping companies navigate FDA approval processes and building world-class management teams. Just don't expect quick exits or patience for pivoting away from hard science.

ARCH is the real deal for deep tech founders who actually have breakthrough science, not just another SaaS tool with AI sprinkled on top. They've been doing this since before 'deep tech' was a buzzword and have the scientific chops to understand what you're building. The flip side? They move slowly, do serious diligence, and won't invest unless they truly believe you're creating something fundamentally new. If you're looking for quick cash to scale a proven model, look elsewhere. But if you've got legitimate IP and need investors who won't panic when your clinical trial takes three years, ARCH is gold.

ARCH is the real deal for deep science and biotech - they've been doing this since before most VCs knew what DNA sequencing was. Bob Nelsen is genuinely one of the smartest biotech investors alive and the team has serious technical chops. They're patient capital that understands long R&D cycles, but they're also tough - they'll push you hard on milestones and scientific rigor. Not the fund for consumer apps or quick flips, but if you're building something that requires PhD-level science and 7-10 year timelines, they're gold standard. They do their homework and won't waste your time if the science doesn't check out.

ARTIS punches above its weight class in the enterprise AI space - they were early on some genuinely good companies like Domino and Cribl when others were still figuring out what MLOps meant. Mike Lazarus has solid technical judgment and doesn't just chase buzzwords. The downside? They're a smaller fund so follow-on capacity can be limited, and they can be pretty hands-on which some founders love but others find intrusive. They're genuine believers in the AI infrastructure thesis, not just tourists, which shows in their portfolio construction.

Jean de Fougerolles has built Ascension into one of London's most active seed funds with genuine operator credibility - both he and partner Remy Minute are exited entrepreneurs who've actually built and sold companies. Their claim to be "the most active VC in London over the past decade" and winning UKBAA's Seed VC of the Year in 2022 isn't just marketing fluff. The Fair By Design fund shows they're serious about impact investing that actually works commercially - companies like Wagestream and Tembo have generated "outsize financial performance" while tackling poverty premium. However, with 300+ portfolio companies, this is spray-and-pray territory where individual attention post-investment becomes mathematically impossible. The EIS/SEIS focus means they're optimizing for tax-efficient investing, which can misalign incentives.

Here's the thing about Ascent: they've actually delivered. Two unicorns (Cult.fit, ACKO), eight IPOs, and ten acquisitions in their portfolio isn't marketing fluff. Their 32 percentage points higher exit rate compared to other VCs shows they know how to get money back to LPs. Raja Kumar brings serious regulatory gravitas - former SEBI official who successfully transitioned from civil service to PE, which is rare in India. The downside? They're conservative - typically less than 2 deals per year, only 1 funding round in the last 12 months. But if you're looking for patient capital from someone who understands Indian markets deeply and has $1 billion under management, they're solid. Just don't expect them to move fast or lead every round.

Atinum is old-school Korean VC royalty - they've been around since 1988 and have serious street cred with multiple unicorns like NIUM and Klook. They're not flashy but they know how to pick winners, especially in Korean tech. The fact that they've expanded to Singapore shows they're thinking beyond Korea's borders. However, like many Korean VCs, they can be pretty hands-off post-investment - don't expect the white-glove treatment of Silicon Valley funds. Their gaming and deep tech focus is solid, and their biotech picks like Celltrion show they can spot big pharma plays. If you're building in Korea or Southeast Asia and need a fund that understands local dynamics but has global ambitions, they're worth talking to.

Atlantic Bridge is the old guard of European tech - they've been doing cross-border deals since before it was cool. Brian Long and team have serious operator credentials (multiple IPOs, actual chip company exits) which matters when you're pitching deep tech. They're not just check-writers - they genuinely help European companies crack the US market through their Palo Alto office and connections. However, note that Atlantic Bridge gradually exited their entire position in Navitas stock in 2025 despite the company's strong showing that year - they know when to take profits. Their exit track record is legitimately impressive: Movidius to Intel, DecaWave to Qorvo, Blue Data to HPE, Hedvig to Commvault, NuVia to Qualcomm. They're particularly strong in semiconductors and enterprise software, but they move slowly and do serious due diligence.

Atlantic Labs is what happens when a successful serial founder (Christophe Maire) decides to back other founders with the same conviction he'd want for himself. Founders consistently say Atlantic is the only fund where you actually get support besides money you can count on - recruiting, strategy, operations. They move fast and aren't afraid of 'too early' or 'too bold' bets. The downside? One anonymous review claimed they were hands-off to the point where a portfolio founder ran wild across jurisdictions, hit a cash wall, and left employees unpaid - suggesting their conviction-based approach might sometimes lack operational oversight. But with 3 unicorns (Choco, GetYourGuide, Omio) in their portfolio, they clearly know how to pick winners.

Atlas is old-school VC done right in biotech — they actually understand the science and have the patience for long development cycles. Bruce Booth is genuinely one of the smartest biotech investors out there, but he's also quite opinionated and will push his views hard. They're great for founders who want strategic guidance and industry connections, less great if you want to be left alone to execute. Their digital health practice is newer and still finding its footing compared to their biotech chops. They move deliberately (sometimes too slowly for Silicon Valley standards) but when they commit, they really commit with follow-on capital and extensive support.

Paula Mariwala is a genuine OG in Indian VC - she was writing checks when most people didn't know what a startup was. The woman has real exits under her belt (RedBus, Carwale) and genuinely knows how to spot talent early. But here's the thing - Aureolis is still finding its identity post-Seedfund days. They talk a big game about 'transformative impact' but their portfolio is all over the map - from Unacademy edtech to coral restoration. Jo Pattabiraman brings solid product chops but she's still proving herself in the investment game. The fund seems to lean heavily on Paula's reputation and Stanford network, which is great for access but founders should expect hands-on mentoring rather than massive checks or aggressive growth strategies.

Austral Capital is essentially a one-person show built around Gonzalo Miranda's extensive Chilean business network. Miranda's Endeavor background gives him serious founder credibility, but this fund has been notably quiet for a decade - their "latest" portfolio company data from most sources is 2012-2015. The recent Zonox investment in late 2024 suggests they're back in action, but with just $200M AUM over 16 years and two exits in 2022, this feels more like a boutique family office than an active VC. The Warburg Pincus exit shows they can deliver returns, but founders should expect a very hands-on, network-heavy approach typical of smaller regional funds. Good for Chilean founders who value deep local connections over fast capital deployment.

Avaana is the real deal in Indian climate tech - they've got conviction, capital ($135M fund with serious LPs including Green Climate Fund), and most importantly, actual exits to show for it. Anjali Bansal isn't your typical VC talking head - she turned around a failing bank and has a track record of backing winners before they were cool. Swapna Gupta cut her teeth at Qualcomm Ventures seeing deep tech early, so she knows how to spot real innovation vs. climate washing. They're not just writing checks - they're building an ecosystem with policy connections, industry linkages, and academic partnerships. The portfolio performance speaks volumes: 3 IPOs, 1 unicorn, and companies like Delhivery and Urban Company that actually scaled. For climate tech founders, this is where you want to be - they understand the long timelines, regulatory complexity, and capital intensity of real climate solutions.